Not applicableLooking for participantsNCT06320717
What this trial is testing
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Who this might be right for
Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute 100